Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. The virtual airway at baseline.
  • Fig. S2. Model parameters and agent interactions.
  • Fig. S3. Flow cytometric analysis of ASM cells.
  • Fig. S4. DK-PGD2, fevipiprant, CAY10471, and OC000459 had no effect on ASM cell number, apoptosis, or necrosis after 24 hours.
  • Fig. S5. DK-PGD2, fevipiprant, and CAY10471 had no effect on ASM proliferation after 72 hours.
  • Fig. S6. DK-PGD2, fevipiprant, and CAY10471 had no effect on basal or BK-induced ASM contraction.
  • Fig. S7. Conceptual summary.
  • Table S1. Description of agents used in computational model.
  • Table S2. Alterations made to epithelial parameters in the computational model.
  • Table S3. Alterations made to mesenchymal parameters in the computational model.
  • Table S4. Alterations made to inflammatory parameters in the computational model.
  • Table S5. Clinical characteristics of subjects that provided additional bronchial biopsies for primary ASM cultures.
  • Table S6. Analysis of expression of genes involved in PGD2 biosynthesis and metabolism in ASM cells.
  • Table S7. Output of computations simulating pathological airway remodeling.
  • References (5170)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Data values for individual experiments.